dm+d

Unassigned

New Medicines

Metastatic pancreatic cancer

Information

New molecular entity
Corcept Therapeutics
Corcept Therapeutics

Development and Regulatory status

None
None
Phase III Clinical Trials
Yes
Yes

Category

Non-steroidal, selective modulator (reduces effect) of the glucocorticoid receptor
Pancreatic cancer is the 11th most common cancer in the UK. It accounts for 3 in 100 of all new cancer cases. There are about 10,000 new pancreatic cancer cases every year, which is 27 new cases per day [2].
Metastatic pancreatic cancer
Oral

Cushing's disease - any cause

Information

Licence extension / variation
Corcept Therapeutics
Corcept Therapeutics

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Non-steroidal, selective modulator (reduces effect) of the glucocorticoid receptor
Endogenous hypercortisolism affects around 0.6 in 10,000 people in the EU; corticotropin-dependent causes account for about 80–85% of cases, and of these, 80% are due to pituitary adenomas with the rest due to ectopic corticotropin syndrome.
Cushing's disease - any cause
Oral